FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.

Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...

Approval of Imfinzi marks the first and only perioperative immunotherapy indicated for muscle-invasive bladder cancer.

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

(HealthDay News) — Avoidable mortality is increasing in the United States and decreasing in comparator countries, according to a study published online March 24 in JAMA Internal Medicine.

Avoidable mortality increased by an average of 33 deaths per 100,000 people across the United States from 2009 to 2019.

HealthDay News — Avoidable mortality is increasing in the US and decreasing in comparator countries, according to a study published online March 24 in JAMA Internal Medicine.

This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder ...

These results suggest that the rise in avoidable mortality is driven by widespread factors across the entire US.

White Mountains Insurance (WTM) shows strong ABVPS growth but faces risks. Discover why it's undervalued and why a hold ...